CAJ | 학술논문

目的探讨新辅助化疗与术后辅助化疗在局部晚期乳腺癌治疗中的临床疗效. 方法选择局部晚期乳腺癌患者56例, 随机分为两组, 新辅助化疗组采用CAF方案, 术前进行2个周期化疗, 术后进行4个周期化疗. 对照组术后采用CAF方案进行6个周期化疗. 比较两组手术切除率,3年生存率,5年局部复发率,5年远处转移率,5年生存率,5年无瘤生存率, 以及治疗前后的CEA, CA-153水平. 结果新辅助化疗组患者的手术切除率, 3年生存率, 5年生存率, 5年无瘤生存率均明显高于对照组, 5年局部复发率和5 年远处转移率明显低于对照组, 统计学均有显著性差异 ( P<0. 05 ).CEA和CA-153水平方面, 新辅助化疗组两种肿瘤标志物水平术后下降明显多于对照组, 具有显著性差异, P<0. 05. 结论新辅助化疗的临床疗效明显优于术后辅助化疗, 值得推广.
목적 탐토신보조화료여술후보조화료재국부만기유선암치료중적림상료효. 방법 선택국부만기유선암환자56례, 수궤분위량조, 신보조화료조채용CAF방안, 술전진행2개주기화료, 술후진행4개주기화료. 대조조술후채용CAF방안진행6개주기화료. 비교량조수술절제솔,3년생존솔,5년국부복발솔,5년원처전이솔,5년생존솔,5년무류생존솔, 이급치료전후적CEA, CA-153수평. 결과 신보조화료조환자적수술절제솔, 3년생존솔, 5년생존솔, 5년무류생존솔균명현고우대조조, 5년국부복발솔화5 년원처전이솔명현저우대조조, 통계학균유현저성차이 ( P<0. 05 ).CEA화CA-153수평방면, 신보조화료조량충종류표지물수평술후하강명현다우대조조, 구유현저성차이, P<0. 05. 결론신보조화료적림상료효명현우우술후보조화료, 치득추엄.
Objective To explore the clinical effects of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy in the treatment of locally advanced breast cancer. Methods 56 patients with locally advanced breast cancer were randomly divided into two groups. The neoadjuvant chemotherapy group was treated with CAF, with 2 cycles of chemotherapy before the surgery and 4 cycles of chemotherapy after the surgery. The control group adopted CAF regimen for 6 cycles of chemotherapy. The surgical resection rate, 3-year survival, 5-year local recurrence, 5-year distant metastasis rate, 5-year survival rate, CEA, CA-153 level before and after the treatment were compared between the two groups. Results The surgical resection rate, 3-year survival rate, 5-year survival rate, 5-year disease-free survival rate of new adjuvant chemotherapy group were significantly higher than those of the control group. 5-year local recurrence rate and 5-year distant metastasis rate were significantly lower than those of the control group. They were significantly different (P<0. 05). The levels of CEA and CA-153, two tumor markers in new adjuvant chemotherapy group were significantly higher than those in the control group. There were significant differences (P<0. 05). Conclusion The clinical effect of neoadjuvant chemo-therapy is better than that of postoperative adjuvant chemotherapy and it is worth popularizing.